Publications by authors named "Wouter Boon"

Claim this Profile
H
How social pharmaceutical innovations are addressing problems of availability, accessibility and affordability of drugs for rare diseases.
Conor M W Douglas, Tineke Kleinhout-Vliek, Rob Hagendijk, Vololona Rabeharisoa, Wouter Boon

Orphanet J Rare Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring scenarios for implementing fast quantitative MRI.
Susan V van Hees, Martin B Schilder, Alexandra Keyser, Alessandro Sbrizzi, Jordi P D Kleinloog, Wouter P C Boon

Eur J Radiol Open· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AI-Assisted Decision-Making in Long-Term Care: Qualitative Study on Prerequisites for Responsible Innovation.
Dirk R M Lukkien, Nathalie E Stolwijk, Sima Ipakchian Askari, Bob M Hofstede, Henk Herman Nap, Wouter P C Boon

JMIR Nurs· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Making Co-Design More Responsible: Case Study on the Development of an AI-Based Decision Support System in Dementia Care.
Dirk R M Lukkien, Sima Ipakchian Askari, Nathalie E Stolwijk, Bob M Hofstede, Henk Herman Nap, Wouter P C Boon

JMIR Hum Factors· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preferred Islet Delivery Device Characteristics and Implantation Strategies of Patients With Type 1 Diabetes.
Maarten C Tol, Denise F A de Bont, Wouter P C Boon, Eelco J P de Koning, Aart A van Apeldoorn

Transpl Int· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the feasibility of introducing triple artemisinin-based combination therapy in the malaria treatment policy in Vietnam.
Van Anh Thi Cao, Thieu Quang Nguyen, Duong Le Quyen, Wouter P C Boon, Ellen H M Moors

Malar J· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An elephant in the glasshouse? Trade-offs between acceleration and transformation in COVID-19 vaccine innovation policies.
Linda van de Burgwal, Tom van der Valk, Hannes Kempter, Manuel Gadau, David Stubbs, Wouter Boon

Environ Innov Soc Transit· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion.
Freek de Haan, Chanaki Amaratunga, Van Anh Cao Thi, Long Heng Orng, Manithong Vonglokham, Wouter P C Boon

Malar J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso.
Rosemonde M Guissou, Chanaki Amaratunga, Freek de Haan, Fatoumata Tou, Phaik Yeong Cheah, Wouter P C Boon

Malar J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs.
Guilherme S Ferreira, Francis M Dijkstra, Désirée H Veening-Griffioen, Wouter P C Boon, Huub Schellekens

Transl Psychiatry· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward Responsible Artificial Intelligence in Long-Term Care: A Scoping Review on Practical Approaches.
Dirk R M Lukkien, Henk Herman Nap, Hendrik P Buimer, Alexander Peine, Wouter P C Boon

Gerontologist· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases.
Conor M W Douglas, Fernando Aith, Wouter Boon, Marina de Neiva Borba, Liliana Doganova

Orphanet J Rare Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the new European Union Diagnostics Regulation on the practice of hospital diagnostic laboratories.
Audrey M M Hermans, Marc Maliepaard, Wouter P C Boon, Anna M G Pasmooij

Expert Rev Mol Diagn· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert perspectives on the introduction of Triple Artemisinin-based Combination Therapies (TACTs) in Southeast Asia: a Delphi study.
Freek de Haan, Wouter P C Boon, Chanaki Amaratunga, Arjen M Dondorp

BMC Public Health· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?
Freek de Haan, Oladimeji Akeem Bolarinwa, Rosemonde Guissou, Fatoumata Tou, Paulina Tindana, Wouter P C Boon

PLoS One· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tradition, not science, is the basis of animal model selection in translational and applied research.
Désirée H Veening-Griffioen, Guilherme S Ferreira, Wouter P C Boon, Christine C Gispen-de Wied, Huub Schellekens

ALTEX· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Market Formation in a Global Health Transition.
Freek de Haan, Ellen H M Moors, Arjen M Dondorp, Wouter P C Boon

Environ Innov Soc Transit· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.
Paulina Tindana, Freek de Haan, Olugbenga Ayodeji Mokuolu, Rosemonde Guissou, Oladimeji Akeem Bolarinwa, Wouter P C Boon

Wellcome Open Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-Hospital Production of Medicines: Preparing for Disruption.
Shona Kalkman, Marlous Arentshorst, Jarno Hoekman, Wouter Boon, Esther Uijtendaal

Trends Biotechnol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of artificial intelligence (AI) applications in radiology: hindering and facilitating factors.
Lea Strohm, Charisma Hehakaya, Erik R Ranschaert, Wouter P C Boon, Ellen H M Moors

Eur Radiol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of drug efficacy in two animal models of type 2 diabetes: A systematic review and meta-analysis.
Guilherme S Ferreira, Désirée H Veening-Griffioen, Wouter P C Boon, Carlijn R Hooijmans, Ellen H M Moors

Eur J Pharmacol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Levelling the Translational Gap for Animal to Human Efficacy Data.
Guilherme S Ferreira, Désirée H Veening-Griffioen, Wouter P C Boon, Ellen H M Moors, Peter J K van Meer

Animals (Basel)· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Future of the drug label: Perspectives from a multistakeholder dialogue.
Christine C Gispen-de Wied, Just Weemers, Wouter Boon, Peter G M Mol, Pieter Stolk

Br J Clin Pharmacol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease.
Désirée H Veening-Griffioen, Guilherme S Ferreira, Peter J K van Meer, Wouter P C Boon, Christine C Gispen-de Wied

Eur J Pharmacol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A standardised framework to identify optimal animal models for efficacy assessment in drug development.
Guilherme S Ferreira, Désirée H Veening-Griffioen, Wouter P C Boon, Ellen H M Moors, Christine C Gispen-de Wied

PLoS One· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis